MRNA logo Moderna +
Moderna
+

Moderna (MRNA) Business News

Track Moderna in real time with a live news feed covering Moderna stock news, official press releases, company announcements, and an archive of historical Moderna news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
2:00 PM | Sunday | Sep 6, 2026 Fox Business

Moderna cancer vaccine BREAKTHROUGH drives new hope after phase 3 trial

News Thumbnail
8:51 AM | Sunday | Sep 6, 2026 MarketBeat

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

News Thumbnail
6:55 AM | Sunday | Sep 6, 2026 The Motley Fool

If You'd Invested in Moderna (MRNA) Stock 5 Years Ago, Here's How Much You'd Have Today (Hint: You'd Be Disappointed -- But Not If You Bought It 1 Year Ago.)

News Thumbnail
8:51 AM | Sunday | Sep 6, 2026 MarketBeat

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

News Thumbnail
6:55 AM | Sunday | Sep 6, 2026 The Motley Fool

If You'd Invested in Moderna (MRNA) Stock 5 Years Ago, Here's How Much You'd Have Today (Hint: You'd Be Disappointed -- But Not If You Bought It 1 Year Ago.)

News Thumbnail
9:51 AM | Saturday | Sep 5, 2026 Schwab Network

Beyond NVDA: New Frontiers in Space Stocks, Healthcare AI

News Thumbnail
3:55 PM | Friday | Sep 4, 2026 The Motley Fool

Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?

News Thumbnail
11:10 AM | Thursday | Sep 3, 2026 The Motley Fool

3 Stocks Whose Competitive Walls Tower Over Nvidia's

News Thumbnail
11:10 AM | Thursday | Sep 3, 2026 Barrons

Why Moderna Stock's Cancer Vaccine Rally Sparked a Rare Sell Rating

News Thumbnail
8:05 AM | Thursday | Sep 3, 2026 247 Wallst

Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More

News Thumbnail
6:36 AM | Thursday | Sep 3, 2026 Seeking Alpha

Moderna: Massive Asymmetry About What The mRNA Is!

News Thumbnail
12:04 PM | Wednesday | Sep 2, 2026 ETF Trends

Why Moderna's Cancer Vaccine Matters to Investors

News Thumbnail
11:31 AM | Tuesday | Sep 1, 2026 Zacks Investment Research

Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough

News Thumbnail

Moderna cancer vaccine BREAKTHROUGH drives new hope after phase 3 trial

Fox Business

2:00 PM | Sunday | Sep 6, 2026

news photo
Loading...

Moderna co-founder and board chairman Noubar Afeyan discusses the phase three success of the Moderna-Merck cancer vaccine trial and explains how the vaccine targets unique mutations to help prevent melanoma recurrence on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #theclamancountdown #moderna #merck #cancer #vaccine #health #medicine #medical #melanoma #science #research #trial #biotech #technology #treatment #breakthrough #healthcare #innovation

Read full article redirect
2:00 PM | Sunday | Sep 6, 2026

Moderna cancer vaccine BREAKTHROUGH drives new hope after phase 3 trial

Fox Business

Moderna co-founder and board chairman Noubar Afeyan discusses the phase three success of the Moderna-Merck cancer vaccine trial and explains how the vaccine targets unique mutations to help prevent melanoma recurrence on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #theclamancountdown #moderna #merck #cancer #vaccine #health #medicine #medical #melanoma #science #research #trial #biotech #technology #treatment #breakthrough #healthcare #innovation

Read full article arrow
News Thumbnail
8:51 AM | Sunday | Sep 6, 2026

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

MarketBeat

Drug pricing is back on the front page, and healthcare investors have barely flinched. The White House's latest round of most-favored-nation pricing agreements brought nine more manufacturers into the fold, pushing the total to 26 companies covering 89% of the branded drug market.

Read full article arrow
News Thumbnail
6:55 AM | Sunday | Sep 6, 2026

If You'd Invested in Moderna (MRNA) Stock 5 Years Ago, Here's How Much You'd Have Today (Hint: You'd Be Disappointed -- But Not If You Bought It 1 Year Ago.)

The Motley Fool

Moderna has had great success with its mRNA technology used for vaccines. Its promising trial results for a cancer vaccine have many investors excited.

Read full article arrow
News Thumbnail
8:51 AM | Sunday | Sep 6, 2026

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

MarketBeat

Drug pricing is back on the front page, and healthcare investors have barely flinched. The White House's latest round of most-favored-nation pricing agreements brought nine more manufacturers into the fold, pushing the total to 26 companies covering 89% of the branded drug market.

Read full article arrow
News Thumbnail
6:55 AM | Sunday | Sep 6, 2026

If You'd Invested in Moderna (MRNA) Stock 5 Years Ago, Here's How Much You'd Have Today (Hint: You'd Be Disappointed -- But Not If You Bought It 1 Year Ago.)

The Motley Fool

Moderna has had great success with its mRNA technology used for vaccines. Its promising trial results for a cancer vaccine have many investors excited.

Read full article arrow
News Thumbnail
9:51 AM | Saturday | Sep 5, 2026

Beyond NVDA: New Frontiers in Space Stocks, Healthcare AI

Schwab Network

Sydney Armani, CEO of AI Fintech World Group, discusses Nvidia (NVDA) continuing its climb after a stellar earnings report, with 2028 revenue projections soaring and its dominance in data center code and software cementing its leadership. Beyond Nvidia, emerging opportunities are drawing attention, including the space economy's focus on orbital data centers and satellite communication, where data infrastructure offers the real opportunity.

Read full article arrow
News Thumbnail
3:55 PM | Friday | Sep 4, 2026

Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?

The Motley Fool

Moderna's shares have pulled back since their most recent highs. The biotech's latest clinical milestone makes its prospects far more attractive.

Read full article arrow
News Thumbnail
11:10 AM | Thursday | Sep 3, 2026

3 Stocks Whose Competitive Walls Tower Over Nvidia's

The Motley Fool

Tech giant Nvidia has remained ahead of rivals thanks to its competitive advantage. These healthcare companies have proven expertise in their fields -- and they would be difficult to unseat.

Read full article arrow
News Thumbnail
11:10 AM | Thursday | Sep 3, 2026

Why Moderna Stock's Cancer Vaccine Rally Sparked a Rare Sell Rating

Barrons

Rothschild analyst Simon Baker downgrades Moderna stock to Sell from Neutral while doubling his price target.

Read full article arrow
News Thumbnail
8:05 AM | Thursday | Sep 3, 2026

Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More

247 Wallst

Markets wobble heading into the Labor Day weekend as bond vigilantes push back against Washington, oil stays tense with Middle East strikes escalating, and Wall Street analysts make bold calls on names ranging from Broadcom to Moderna that could reshape your portfolio positioning.

Read full article arrow
News Thumbnail
6:36 AM | Thursday | Sep 3, 2026

Moderna: Massive Asymmetry About What The mRNA Is!

Seeking Alpha

Moderna receives a speculative Strong Buy rating after phase 3 melanoma data strengthens its oncology platform thesis. MRNA's upside hinges on Intismeran's ability to scale across multiple tumor types, not just melanoma. The 50/50 partnership with Merck provides both distribution strength and shared economics for Intismeran.

Read full article arrow
News Thumbnail
12:04 PM | Wednesday | Sep 2, 2026

Why Moderna's Cancer Vaccine Matters to Investors

ETF Trends

Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.

Read full article arrow
News Thumbnail
11:31 AM | Tuesday | Sep 1, 2026

Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough

Zacks Investment Research

Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.

Read full article arrow
News Thumbnail